The immune landscape of BlCa is very rich; several immune-cell populations reside in the urinary bladder, and immunotherapies have the advantage of modulating them, namely activating favorable immune populations such as CD8+ T-lymphocytes and Th1 CD4 αβ T-lymphocytes [18]. Here, CD4 is linked to bladder transitional cell carcinoma.